[HTML][HTML] Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib
Y Kim, SH Lee, JS Ahn, MJ Ahn, K Park… - Cancer Research and …, 2019 - ncbi.nlm.nih.gov
Purpose We tried to evaluate whether there are any specific features in treatment outcomes
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of …
T Kato, H Yoshioka, I Okamoto, A Yokoyama… - Cancer …, 2015 - Wiley Online Library
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen, K Park… - The lancet …, 2012 - thelancet.com
Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer
GM Keating - Drugs, 2014 - Springer
Abstract Afatinib (Gilotrif™, Giotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently …
ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently …
[HTML][HTML] First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne, L Zhang… - Journal of cancer …, 2019 - Springer
Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
Afatinib: a review in advanced non-small cell lung cancer
GM Keating - Targeted oncology, 2016 - Springer
Abstract Afatinib (Giotrif®, Gilotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. In the first-line treatment of patients with advanced lung …
ErbB family of tyrosine kinases. In the first-line treatment of patients with advanced lung …
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
K Park, D Wan-Teck Lim, I Okamoto… - … advances in medical …, 2019 - journals.sagepub.com
Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …